An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma

Trial Profile

An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Encapsulated cell therapy (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms Macrobead
  • Most Recent Events

    • 02 Jun 2017 Results from NCT01053013 and NCT00283075 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 28 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2018.
    • 28 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top